UK markets close in 7 hours 27 minutes

Kanabo Group Plc (KNB.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
16.31-0.19 (-1.15%)
As of 8:45AM BST. Market open.
Sign in to post a message.
  • S
    If anyone's on this board, what are your opinion on the future of Kanabo? I'm still yet to do research on the company, so just looking for your outlook(s)
  • N
    NYI No1
    Is KNB putting out any financials? I can't find any quarterly financials. Income statement, Balance sheet, cash flow, etc.. Hard to figure our how they are performing.
  • S
    haven't been paying much attention to this since I bought in. anyone hazard a guess to what way it'll go? like will we eventually get a reverse split? or are we expecting the current share price to shoot up?
  • C
    OK, so is NOW a good time to start talking these up again?
  • N
    NYI No1
    I think investors are waiting to see if KNB can generate significant sales & growth to support its valuation. The big boys (CuraLeaf and Tilray) are already in Europe. KNB hasn't really sold anything yet. When they start putting out full quarterly financials and MD&A reports will we know what they have. Right now it's only a plan. That is why the stock hasn't really moved. It needs to show some real numbers and not just press releases.
  • D
    it jumped over the news of it going to be Europes biggest medicinal cannabis stock, and I think at that point a lot of people that have been bag holding this for a while have jumped ship when it shot up. it's never going to be a smooth rise to the top, it's gonna be up and down for a while yet I think.
  • M
    What am I missing, why are we down 10% today ?
  • M
    hold and buy more buy more and hold this will be over £1 in no time at all.
  • B
    steady away
  • B
    Can't wait until KNB reaches £1 and over.
  • D
    What happened today??
  • A
    Green for 10 days in a row and up 60 % . This is finally taking off.
  • J
    Technicals says this baby will rip big on the next catalyst. Eyes on
  • R
    wow last week's gains almost wiped
  • B
    slow and steady before the bull run
  • C
    Business Wire
    Newly Listed on LSE, Kanabo Group Announces Partnership With the UK’s Biggest Cannabis Clinic Provider, LYPHE Group
    Tue, 23 February 2021, 10:33 am·2-min read
    Kanabo Group Plc, a medical cannabis company that recently debuted on London Stock Exchange, is delighted to announce it has signed its first UK medicinal cannabis distribution framework agreement with Astral Health Limited ("Astral Health"). Astral Health is fully owned by LYPHE Group, which is part of Drug Science’s Project Twenty21. According to the agreement, Kanabo will supply its medical-grade inhalation device, VapePod® and a line of medicinal cannabis formulations in pods for the UK market.

    Through this new framework agreement, it is intended that Kanabo’s VapePod medicinal cannabis formula, under brand NOIDECS will be made available to Project Twenty21 patients. Project Twenty21 provides eligible patients with affordable medical cannabis treatment, monitored by Drug Science. The project aims to create the UK's largest body of evidence for the effectiveness and tolerability of medical cannabis.

    The VapePod will be the first product of its kind, a medical-grade handheld vaporiser with controlled metered dosage, made available to UK cannabis patients with a medical prescription. The initial formula, which Astral Health will distribute under the name NOIDECS 400T, is based on the Israeli medical cannabis pharmacopoeia as a recommended ratio for pain management. Kanabo and Astral Health will work closely together to make the products available to patients over the next 3-6 months.

    Scroll to continue with contentAd

    Perfect business partners
    EE Business UK
    Perfect business partners
    The new Galaxy on the UK's No.1 network. Get it with unlimited data, and a choice of BT Sport, Britbox or Prime Video. Prices exc. VAT. T&Cs apply.
    Avihu Tamir, Kanabo's CEO commented: "We believe this new product will be revolutionary for medical cannabis patients who need immediate relief of pain, and will replace the smoking of cannabis flowers as a medical delivery method, which is one of Kanabo's main targets."

    Dean Friday, LYPHE’s CEO commented: "We have seen the headlines, and we have witnessed the negative impact of opioids. Pain is not going to go away, so a more natural and caring approach to treating it must find centre stage. Thanks to our partnership with Kanabo we now have a metered dose NOIDECS product that can treat patients across the U.K. that suffer from chronic pain."

    About LYPHE Group:
    LYPHE Group, delivers a patient-focused medical cannabis ecosystem, and has emerged as the UK’s market leader in patient care – seeing over 60% of the medical cannabis patients in the country. LYPHE delivers a reliable and seamless supply of medical cannabis care and medicine. It has built a patient-access ecosystem across the UK that provides clinics, pharmacy & dispensing, import infrastructure and vital educational services to patients, doctors and other health care professionals.

    About Kanabo
    Kanabo is a medical cannabis company based in the UK and Israel, provides innovative solutions for the medical cannabis industry. Having built a medically validated IP that includes delivery systems working with patented formulations, Kanabo's Initial product development is focused on vaporisation, including both medical grade vaporisers and formulations of medical cannabis extracts.
  • A
    Ooh, hello, +8%.
    Is it too early to start talking these up again?
  • G
    9 March 2021Kanabo Group Plc("Kanabo" or "The Company")Medicinal Cannabis Production Agreement Kanabo Group Plc (LSE:KNB), is pleased to announce that it has signed a production and supply agreement with PharmaCann Polska ("PharmaCann") under which PharmaCann will supply cartridges containing Kanabo's proprietary medicinal cannabis formulations for its VapePod inhalation device. The cartridges will be filled and prepared at PharmaCann's wholly owned facility in North Macedonia. This is a second key agreement directed towards establishing a European medicinal cannabis supply chain and builds on the previous announcement of a UK distribution agreement. Kanabo's CBD Wellness products are already being produced and distributed in the primary markets of UK and Germany.
    PharmaCann, based in Warsaw, is a part of the PHCANN International Group. Its fully licensed compound in Skopje, North Macedonia comprises both an indoor cultivation facility and an EU-GMP standard extraction facility for production of products based on cannabinoids. According to the agreement, PharmaCann and Kanabo will establish a dedicated production line for medicinal formulas that will use filling equipment procured and supplied by Kanabo and Kanabo's production protocols. Under the agreement, PharmaCann provides an initial production capacity of up to 36,000 cartridges per month with the ability to further increase production when necessary.

    The production and supply agreement gives Kanabo full visibility and control over product quality from hydroponic, pesticide-free cultivation through to extraction, filling and distribution of tamper-proof cartridges designed to work with its medical-grade VapePod inhalation device.
    Avihu Tamir, CEO Kanabo Group Plc said: "Following the increased fund-raise achieved at the IPO, we are able to accelerate preparations for supply of medicinal cannabis products in addition to building our CBD Wellness business. I am delighted to work with PharmaCann which will enable us to provide medical cannabis vape products to thousands of patients safely and effectively using our medical grade VapePod device."
  • A
    Kanabo is set to become Europe's largest Cannabis company once it acquires Materia.
  • j
    Shares in Kanabo Group PLC (LSE:KNB) are higher after the medical cannabis group unveiled a manufacturing deal for its products.
    It said Pure Origin Group will manufacture, package and supply Kanabo's cannabidiol (CBD) range from its manufacturing facility in Wales, which uses EU good manufacturing practices - a system to ensure finished products are effective and safe for distribution.
    Pure Origin and Kanabo will establish a dedicated production line for the VapePod's CBD Wellness formulas that will use Kanabo's equipment, production protocols and IP.
    Kanabo will supply raw materials to Pure Origin for the preparation of CBD formulations and final packaging. The current production line will have an initial capacity of 44,000 units a month with the ability to further increase production when necessary.
    The company said the new agreement marked the end of the period of pilot sales and was the prelude to a full product launch internationally.
    Its long-term strategy involves continued research and development activities to develop a range of unlicensed medical cannabis oils, which will be sold as unlicensed medical products.
    Kanabo is up 6.38% at 20p.